Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway

Jin Zhou | Yuan-yuan Jiang | Huan Chen | Yi-chao Wu | Li Zhang

Abstract

Objectives: Tanshinone I (Tan-I) is one of the vital fatsoluble monomer components, which extracted from Chinese medicinal herb *Salvia miltiorrhiza* Bunge. It has been shown that Tan-I exhibited anti-tumour activities on different types of cancers. However, the underlying mechanisms by which Tan-I regulates apoptosis and autophagy in ovarian cancer remain unclear. Thus, this study aimed to access the therapy effect of Tan-I and the underlying mechanisms.

Methods: Ovarian cancer cells A2780 and ID-8 were treated with different concentrations of Tan-I (0, 1.2, 2.4, 4.8 and 9.6 μg/mL) for 24 hours. The cell proliferation was analysed by CCK8 assay, EdU staining and clone formation assay. Apoptosis was assessed by the TUNEL assay and flow cytometry. The protein levels of apoptosis protein (Caspase-3), autophagy protein (Beclin1, ATG7, p62 and LC3II/LC3I) and PI3K/AKT/mTOR pathway were determined by Western blot. Autophagic vacuoles in cells were observed with LC3 dyeing using confocal fluorescent microscopy. Anti-tumour activity of Tan-I was accessed by subcutaneous xeno-transplanted tumour model of human ovarian cancer in nude mice. The Ki67, Caspase-3 level and apoptosis level were analysed by immunohistochemistry and TUNEL staining.

Results: Tan-I inhibited the proliferation of ovarian cancer cells A2780 and ID-8 in a dose-dependent manner, based on CCK8 assay, EdU staining and clone formation assay. In additional, Tan-I induced cancer cell apoptosis and autophagy in a dose-dependent manner in ovarian cancer cells by TUNEL assay, flow cytometry and Western blot. Tan-I significantly inhibited tumour growth by inducing cell apoptosis and autophagy. Mechanistically, Tan-I activated apoptosis-associated protein Caspase-3 cleavage to promote cell apoptosis and inhibited PI3K/AKT/mTOR pathway to induce autophagy.

Conclusions: This is the first evidence that Tan-I induced apoptosis and promoted autophagy via the inactivation of PI3K/AKT/mTOR pathway on ovarian cancer and further inhibited tumour growth, which might be considered as effective strategy.
1 | INTRODUCTION

Ovarian cancer is the second cancer of the female reproductive system and the leading cause of death from gynaecologic malignancies.1,2 Five years after diagnosis (five-year survival), survival for ovarian cancer in women was 45.0%. Although age-standardized rates are stable or falling in most high-income countries, they are rising in many low- and middle-income countries.3 Because ovarian cancer is often diagnosed late and composed of several subtypes with distinct biological and molecular properties, and there is inconsistency in availability of and access to treatment. Upfront treatment largely relies on debulking surgery and platinum-based chemotherapy, with the addition of anti-angiogenic agents in patients.4 Despite much progress for the treatment of ovarian cancer in recent years, an important problem in tumour therapy with compounds is the development of drug resistance and side effects.5,6 Most established compounds suffer from insufficient specificity towards tumour cells. So the identification of improved anti-tumour drugs is urgently needed.

Salvia miltiorrhiza, also known as Dan-shen, is the Chinese traditional herb and widely used in the clinic for the treatment of cardiovascular diseases. The main pharmacologically active components of Dan-shen are tanshinones, which have many pharmacological activities, such as cardiovascular protection activities, anti-inflammatory, anti-hepatic fibrosis and anti-tumour.7–10 The tanshinones consist of four major constituents, such as tanshinone I (Tan-I), tanshinone IIA, cryptotanshinone and dihydrotanshinone I, and their biological effects have been a prime research focus.11–14 The major constituents of Dan-shen have been recently shown to possess some activities against human cancer cells. Cryptotanshinone significantly inhibited the growth of hepatocarcinoma cells and breast carcinoma cells in vitro via influencing cell cycle.15,16 Tanshinone IIA inhibited the growth of breast cancer, glioma, leukemia and hepatocellular carcinoma cells in vitro by induction of apoptosis.17–20 Tan-I inhibited the growth of leukemia, colorectal, lung and breast cancer in vitro by induction of apoptosis and anti-angiogenesis activity.21–25 We recently found that Tan-I inhibited the proliferation of ovarian cancer cells in vitro, with Tan-I being the most potent agent. But whether there are other anti-cancer mechanisms is unknown.

Macroautophagy (hereafter referred to as autophagy) is the process by which cells package and degrade cytosolic components, and recycle the breakdown products for future use.26–28 In normal cells, autophagy could act as a brake to prevent tumorigenesis, but cancer cells are able to hijack this process to their own benefit, to promote tumour growth and/or tumour resistance to anti-cancer therapies.29,30 However, deregulated or excessive autophagy could cause autophagic cell death, also known as the type II programmed cell death.31–33 Autophagy-dependent cell death provides molecular mechanisms and implications for cancer therapy.

In our study, we determined the effects of Tan-I on the proliferation of ovarian cancer cell lines in vitro and the effect of Tan-I on the growth of ovarian cancer cell A2708 tumours in mice. We also analysed apoptosis and autophagy level of ovarian cancer cells during Tan-I treatment.

2 | MATERIALS AND METHODS

2.1 | Tan-I preparation from Dan-shen

To obtain Tan-I extracts, 10 g crude material of Dan-shen was subjected to extraction and purification according to the following procedures.34–36 Crushed powder was added into 100 mL of ethanol, and extracted twice for 30 minutes with refluxing, filtered, and combined with filtrate. Recovering ethanol on vacuum at 60°C, and concentrated to thick paste with relative density of 1.30 ~ 1.35 g/mL. Next, wash it with hot water until the washing liquid is colourless and dry at 80°C to obtain a crude extract of Tan-I. Finally, the crude extract of Tan-I was dissolved in 61% acetonitrile to prepare a saturated solution for the purification of Tan-I.

Tan-I was separated and purified by semi-preparative high-performance liquid chromatography. Tan-I was separated and purified on Megres C18 column (30 × 250 mm, 10 μm). The binary mobile phase consisted of 0.1% phosphoric acid in water (solvent A) and acetonitrile (solvent B). The flow rate was 42.0 mL/min. The detection wavelength was 270 nm. The separation of Tan-I was performed using a gradient elution: 61% B for 0-6 minutes, 61%-90% B for 6-25 min, 90%-61% B for 25.5-30 minutes. The saturated tanshinone solution was filtrated through 0.22 μm filter membrane, and the injection volume was 10 mL. The eluent peak of Tan-I was collected and filtered to obtain Tan-I crystal.

Tan-I crystal was prepared into a sample solution with a concentration of 0.2 mg/mL. The purity of the Tan-I crystal solution was determined by HPLC according to the Chinese Pharmacopoeia. The purity of Tan-I was 94.2%. Tanshinone I obtained is used in the following experiments.

2.2 | Cell culture

The human A2780, Skov3, HOSEpic and mouse ID-8 cell lines were obtained from American Type Culture Collection (ATCC, USA). The cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Hyclone, USA) supplemented with 10% foetal bovine serum (FBS, Hyclone, USA), penicillin and streptomycin (100 U/mL, Hyclone, USA) in a humidified incubator with 5% CO2 at 37°C.

2.3 | CCK8 assay

Cell viability was analysed by Cell Counting Kit-8 (CCK8, Beyotime, Shanghai, China) according to the manufacturer’s protocols. Cells
were seeded and cultured at a density of $5 \times 10^3$ cells/well in 100 μL of medium into 96-well microplates (Corning, USA). Then, the cells were treated with various concentrations of Tan-I (0, 1.2, 2.4, 4.8 and 9.6 μg/mL). After treatment for 24 hours, 10 μL of CCK-8 reagent was added to each well and then cultured for 2 hours. All experiments were performed in triplicate. The absorbance was analysed at 450 nm using a microplate reader (Bio-Rad, Hercules, CA, USA) using wells without cells as blanks. The proliferation of cells was expressed by the absorbance.

2.4 | Colony formation assay

A2780 and ID-8 cell lines were seeded and cultured into the six-well plate at a density of $1 \times 10^3$ cells/well in DMEM containing 10% FBS for 24 hours. Then, the cells were treated with various concentrations of Tan-I (0, 1.2, 2.4, 4.8 and 9.6 μg/mL). After the treatment, these disposed cells were then re-suspended in DMEM containing 10% FBS and cultured in 5% CO$_2$ at 37°C for 15 days to allow colony formation. The plate was washed with cold PBS. The colonies were fixed by 4% polyformaldehyde at room temperature. Next, they were dyed with 1% crystal violet for 30 minutes at room temperature. The colonies more than 100 cells were counted by microscope (Leica Microsystems, Germany). Each experiment was done thrice in this study. Colony formation rate = the number of each treatment/ the number of control × 100%.

2.5 | EDU staining assay

EdU staining was used to analysed the cancer cell proliferation according to the following protocol. Briefly, A2780 and ID-8 cell lines were treated with different concentrations of Tan-I (0, 1.2, 2.4, 4.8 and 9.6 μg/mL) for 24 hours, incubated with EdU (20 mmol/L) for 2 hours. The cells were fixed by 4% paraformaldehyde for 20 minutes at room temperature. EdU-positive cells were analysed in different treatment group.

2.6 | Flow cytometry assay

A2780 and ID-8 cells ($1 \times 10^5$ cells/mL) were grown in DMEM containing 10% FBS for 24 hours on 6-well plates. Then, the cells were treated with various concentrations of Tan-I (0, 1.2, 2.4, 4.8 and 9.6 μg/mL). After the treatment, the treated cells were harvested and washed with cold PBS buffer. The cells were resuspended in binding buffer and stained with 5 μL Annexin V-FITC plus 5 μL propidium iodide (Beyotime, Shanghai, China) in 4°C for 30 minutes in dark. The stained cells were washed by binding buffer for 3 times to remove excess dyes and then resuspended in 500 μL binding buffer. The percentage of apoptosis were analysed by using flow cytometry (BD, FACSCalibur, USA) within 1 hour. The experiment was repeated three times.

2.7 | TUNEL assay

The TUNEL assay was analysed according to the kit protocol (Vazyme Biotech Co., Ltd, China). Briefly, the sections of tumour tissue were deparaffinized in xylene and rehydrated in PBS buffer. The sections were incubated with 15 μg/mL proteinase K for 20 minutes at 37°C. After washing three times with PBS buffer, the sections were incubated in 1× equilibration buffer for 30 minutes, then incubated with a mixture containing 50 μL of Biotin-dUTP Labeling Mix and 3 μL of TdT Enzyme for 1 hour at 37°C in the dark. Then, the slides were incubated with 100 μL stopping buffer for 10 minutes and then rinsed in PBS three times. The specimen was covered in Streptavidin-HRP for 30 minutes and washed in PBS three times. The slides were visualized by DAB substrate and observed by microscope (OLYMPUS, Japan). TUNEL-positive cells were counted, and the apoptotic index was calculated as a ratio of (apoptotic cell number)/(total cell number) in each field.

2.8 | Tumour xenograft assay

Female 4- to 6-week-old BALB/c nude mice were obtained from Nanjing model animal research centre, and mouse research procedures in vivo were performed according to the Animal Care Committee of Sichuan agriculture university. The tumour model of mice was obtained by subcutaneously injecting of A2780 cells (100 mL, $2 \times 10^7$ cells). When tumour volume had reached a volume of about 150 mm$^3$, the mice were randomly divided into control groups and Tan-I group (30 mg/kg). The mice in Tan-I group were treated with 30 mg/kg Tan-I, and the mice in control group were treated with an equivalent volume of dimethyl sulfoxide (DMSO). The drug in control group and Tan-I group was administered by i.p. injection once every three days. The tumour length (L) and width (W) were obtained by caliper, and tumour volumes were calculated using the formula: $V = \frac{L \times W^2}{2}$. The tumour weight was weighed after the end of treatment.

2.9 | Western blotting assay

Total protein from the treated cells and tissues were extracted by RIPA buffer containing 1 mmol/L PMSF (Beyotime, Shanghai, China) and quantified using the BCA Protein Assay Kit (Beyotime, Shanghai, China). Protein bands were separated by SDS-PAGE and then transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore). After blocking with 5% bovine serum albumin (BSA) in phosphate-buffered saline with Tween (PBST) for 1 hour, the PVDF membrane was incubated with primary antibodies at 4°C overnight. After washing three times, the membrane was incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hour at room temperature. Finally, enhanced chemiluminescence (ECL Kit, Advansta) was used to visualize the immunoblot according to protocol. The intensity of the Western bands was determined by ImageJ software (version 1.46; National Institutes of Health (NIH): Bethesda, USA).
2.10 | Immunohistochemistry and HE staining

Tumour tissues were isolated from mice after mice were sacrificed. The tissues were immediately fixed in 4% paraformaldehyde for 24 hours and embedded in paraffin. The embedded sections were sliced into 5 μm sections for staining. The deparaffinized and rehydrated sections were heated in citrate buffer at 121°C for 30 minutes to retrieve antigenic activity. The sections were incubated with 0.3% hydrogen peroxide in methanol for 30 minutes to inhibit endogenous peroxidase activity. After non-specific reactions had been blocked with 10% normal bovine serum, the sections were incubated with rabbit polyclonal antibodies specific to Caspase-3 (#9662, Cell Signaling Technology, USA) and Ki67 (#9129, Cell Signaling Technology, USA) at 4°C for 12 hours. Then, the sections were washed by PBS and incubated with horseradish peroxidase-conjugated secondary antibody at 37°C for 2 hours. The sections were counterstained with haematoxylin for detection. The major organs including the heart, liver, spleen, lung and kidney were isolated from mice after mice were sacrificed. The obtained organs were fixed with 4% paraformaldehyde overnight. Afterwards, these organs were dehydrated in 25% sucrose, sectioned into 5 μm slices and stained with haematoxylin and eosin (H&E). The stained sections were imaged under an inverted phase contrast microscope.

2.11 | Statistical analysis

The results are presented as mean ± SD. Data were assessed using the software SPSS 19.0. Statistical significance for comparisons among two or three groups was analysed using the Student t test or one-way ANOVA, respectively. P values of less than .05 were considered as statistically significant.

3 | RESULTS

3.1 | Tan-I inhibited proliferation and colony formation in ovarian cancer cell

For the exploration of the activity of Tan-I in proliferation of ovarian cancer cell, CCK-8 assays and EDU staining were used to detect the viability of ovarian cancer cells (A2780, Skov3 and ID-8) after treatment with various concentrations of Tan-I for 24 hours. As presented in Figure 1A, Tan-I inhibited the growth of ovarian cancer cells in a dose-dependent manner. However, Tan-I did not inhibit the growth of normal ovarian cells in a dose-dependent manner (Figure 1A). Compared with Skov3 cells, Tan-I at 2.4, 4.8 and 9.6 μg/mL induced about 50% growth inhibition in A2780 and ID-8 ovarian cancer cells, so A2780 and ID-8 cell lines were utilized in the following experiments in vitro and in vivo. Western blot assay indicated that Tan-I reduced the Ki67 protein expression in A2780 cells and ID-8 cells in a dose-dependent manner (Figure 1B). Furthermore, colony formation assay indicated that Tan-I markedly inhibited proliferation in A2780 cells and ID-8 cells (Figure 1C). In addition, EdU assay results showed that the EdU-positive cells were markedly inhibited in dose-dependent manner by Tan-I treatment (Figure 1D). These results suggested that Tan-I could suppress proliferation and colony formation in A2780 cells and ID-8 cells.

3.2 | Tan-I induced the apoptosis in ovarian cancer cell

To estimate the effect of Tan-I on apoptosis, flow cytometry analysis using double staining with annexin V-FITC/PI was performed in A2780 and ID-8 cells. After being treated with Tan-I (0.12, 2.4, 4.8 and 9.6 μg/mL) for 24 hours, compared with the untreated cells, the apoptotic cells in the treated cells significantly increased in a dose-dependent manner (Figure 2A,B). Tan-I induced the major population of A2780 and ID-8 cells into the late apoptotic stage at 9.6 μg/mL concentration. TUNEL staining showed that the number of apoptotic cells gradually increased with the increase in Tan-I concentration (Figure 2C,D). To further explore the mechanism by which Tan-I induced cell apoptosis, Western blotting was utilized to detect the expressions of Caspase-3. The results showed that Tan-I markedly promotes Caspase-3 cleavage in A2780 and ID-8 cells in a dose-dependent manner compared with the control cells (Figure 2E,F and G). In additional, Bcl-2 expression significantly reduced and Bax significantly increased in A2780 and ID-8 cells in a dose-dependent manner compared with the control cells (Figure 2E,F and H). These data suggested that Tan-I promoted apoptosis via promoting Caspase-3 cleavage.

3.3 | Tan-I activated the autophagy pathway in ovarian cancer cell

To estimate the effect of Tan-I on autophagy, autophagic activity was analysed in A2780 and ID-8 cells. Western blotting results showed that the expressions of autophagy-related proteins Beclin1 and ATG7 dramatically increased in a dose-dependent manner in A2780 and ID-8 cells. Furthermore, Tan-I significantly promoted the turnover of LC3-II and p62 degradation (Figure 3A). These data revealed that Tan-I induced autophagy. In additional, immunofluorescence data indicated that Tan-I increased the level of LC3-II in a dose-dependent manner in A2780 and ID-8 cells, which positively related to autophagosome formation (Figure 3B). Furthermore, autophagic inhibitor 3-MA was used to further testify autophagic activation effect of Tan-I in A2780 and ID-8 cells. The results revealed that autophagy associated proteins Beclin1 and Atg7 markedly downregulated and the turnover of LC3-II and p62 degradation significantly inhibited in 3-MA treated A2780 and ID-8 cells (P < .05) (Figure 3C). But when cells were co-stimulated by 3-MA and Tan-I, Beclin1 and Atg7 expression level significantly enhanced and the turnover of LC3-II and p62 degradation were rescued compared with cells that were treated by 3-MA alone (P < .05) (Figure 3C). Immunofluorescence results further confirmed this phenotype (Figure 3D). All these results suggested that Tan-I could induce autophagy in A2780 and ID-8 cells.
To investigate the mechanism by which Tan-I induced autophagy, Western blotting was utilized to detect PI3K/AKT/mTOR pathway. The results showed that the ratio of p-PI3K/PI3K, p-AKT/AKT and p-mTOR/mTOR significantly reduced in a dose-dependent manner in Tan-I treated cells compared with untreated cells (P < .05) (Figure 4A). The ratio of p-PI3K/PI3K, p-AKT/AKT and p-mTOR/mTOR in Tan-I and 3-MA co-treated cells markedly downregulated than that of 3-MA or Tan-I alone (P < .05) (Figure 4B). EDU staining and TUNEL assay showed that Tan-I plus 3-MA treatment significantly inhibited cell proliferation and induced cell apoptosis compared with Tan-I or
FIGURE 2  Tan-I induced the apoptosis by promoting Caspase-3 cleavage. A, Apoptosis assay of A2780 and ID-8 cells after Tan-I treatment at 1.2, 2.4, 4.8 and 9.6 μg/mL for 24 h by flow cytometer. B, Quantification of cell apoptosis in (A). Data are shown as mean ± SD. *P < .05. C, The apoptosis-positive cells of A2780 and ID-8 cells after Tan-I treatment at 1.2, 2.4, 4.8 and 9.6 μg/mL for 24 h by TUNEL staining(×100). D, Quantification of TUNEL-positive cells in (C). Data are shown as mean ± SD. *P < .05. E and F, Apoptosis-related protein expression (Caspase-3, Bcl-2 and Bax) in A2780 and ID-8 cells after Tan-I treatment at 1.2, 2.4, 4.8 and 9.6 μg/mL for 24 h by Western blot. G, Quantification of Caspase-3 activity in (E) and (F). Data are presented as the mean ± SD of three independent experiments. *P < .05. H, The ratio of Bcl-2/Bax in (E) and (F). Data are presented as the mean ± SD of three independent experiments. *P < .05
FIGURE 3  Tan-Ⅰ induced autophagy of ovarian cancer cell. A, The protein expression level of Autophagy associated protein (Beclin1 and Atg7) and autophagic substrate (LC3 and p62) were analysed in A2780 and ID-8 cells after Tan-Ⅰ treatment at 1.2, 2.4, 4.8 and 9.6 μg/mL for 24 h by Western blot. Data are presented as the mean ± SD of three independent experiments. *P < .05. B, LC3 puncta was analysed in A2780 and ID-8 cells after Tan-Ⅰ treatment at 1.2, 2.4, 4.8 and 9.6 μg/mL for 24 h by immunofluorescence assay(×200). Data are shown as mean ± SD. *P < .05. C, The protein expression level of Autophagy associated protein (Beclin1 and Atg7) and autophagic substrate (LC3 and p62) in A2780 and ID-8 cells after Tan-Ⅰ, 3-MA or Tan-Ⅰ plus 3-MA treatment for 24 h by Western blot. Data are presented as the mean ± SD of three independent experiments. Compare to Tan-Ⅰ (4.8 μg/ml) *P < .05; compare to 3-MA + Tan-Ⅰ (4.8), #P < .05. D, LC3 puncta was analysed in A2780 and ID-8 cells after Tan-Ⅰ, 3-MA or Tan-Ⅰ plus 3-MA treatment for 24 h by immunofluorescence assay(×200). Data are shown as mean ± SD. Compare to Tan-Ⅰ (4.8 μg/ml) *P < .05; compare to 3-MA + Tan-Ⅰ (4.8), #P < .05
FIGURE 4 Tan-I inhibited PI3K/AKT/mTOR pathway. A, Phosphorylation levels of PI3K, AKT and mTOR in A2780 cells after Tan-I treatment at 1.2, 2.4, 4.8 and 9.6 μg/mL for 24 h by Western blot. Data are presented as the mean ± SD of three independent experiments. *P < .05. B, Phosphorylation levels of PI3K, AKT and mTOR in A2780 cells after Tan-I, 3-MA or Tan-I plus 3-MA treatment for 24 h by Western blot. Data are presented as the mean ± SD of three independent experiments. Compare to Tan-I (4.8 μg/mL) *P < .05; compare to 3-MA + Tan-I (4.8), *P < .05. C, Percentage of EdU-positive cells of A2780 cells after Tan-I, 3-MA or Tan-I plus 3-MA treatment for 24 h by EdU staining (x100). Data are shown as mean ± SD. Compare to Tan-I (4.8 μg/mL) *P < .05; compare to 3-MA + Tan-I (4.8), *P < .05. D, The apoptosis-positive cells of A2780 and ID-8 cells after Tan-I, 3-MA or Tan-I plus 3-MA treatment for 24 h by TUNEL staining (x100). Data are shown as mean ± SD. Compare to Tan-I (4.8 μg/mL) *P < .05; compare to 3-MA + Tan-I (4.8), *P < .05.

FIGURE 5 Tan-I inhibited tumour growth in vivo. A, Tumours in control group and Tan-I 30 mg/mL group were isolated and pictured after 4 weeks' treatment. B, Tumour weight was calculated in control group and Tan-I 30 mg/mL group. Data are shown as mean ± SD. *P < .05. C, Tumour growth curve in control group and Tan-I 30 mg/mL group. Data are shown as mean ± SD. *P < .05. D, Ki67 and Caspase-3 protein expression in tumour tissues of control group and Tan-I 30 mg/mL group were analysed by immunohistochemistry (x40). Tumour cell apoptosis in control group and Tan-I 30 mg/mL group were analysed by TUNEL staining (x40). E, Quantification of protein expression and cell apoptosis in (D). Data are shown as mean ± SD. *P < .05. F, The protein expression of autophagy and PI3K/Akt/mTOR signalling pathway in control group and Tan-I 30 mg/mL group were detected by Western blot. n = 3. G, Quantification of protein expression in (F). Data are shown as mean ± SD. *P < .05.
3-MA alone (P < .05) (Figure 4C, D). These data showed that Tan-I inhibited cell proliferation by PI3K/AKT/mTOR pathway.

3.5 | Tan-I inhibited tumour growth in vivo

In order to evaluate the anti-tumour effect of Tan-I in vivo, A2780 tumour bearing xenograft was constructed and treated. The results showed that tumour weight and tumour growth in 30 mg/kg Tan-I group markedly reduced than that of control group (P < .05) (Figure 5A, B and C). As shown in Figure 5D, Ki67 positive ratio in 30 mg/kg Tan-I group significantly inhibited compared with control group (P < .05). Caspase-3-positive cells and tumour apoptosis index in 30 mg/kg Tan-I group significantly enhanced than that of control group (P < .05) (Figure 5D and E). Western blot results showed that p-PI3K/ PI3K, p-AKT/AKT and p-mTOR/mTOR in 30 mg/kg Tan-I group significantly inhibited compared with control group (P < .05) (Figure 5F and G). In additional, autophagy associated protein Beclin1 and Atg7 level in 30 mg/kg Tan-I group significantly increased than that of control group (P < .05) and ratio of LC3-II/LC3-I and p62 degradation obviously enhanced than that of control group (P < .05) (Figure 5F and G). These data showed that Tan-I could inhibit tumour growth by activating apoptosis and inducing autophagy. The results of HE pathological sections of mice major organs (heart, liver, spleen, lung and kidney) indicated that Tan-I treatment had no evident damage to the major organs of mice (Figure 6A, B, C, D and E). As shown in Figure 6F, no significant decrease of weight was observed after mice were treated with Tan-I compared with control group.

4 | DISCUSSION AND CONCLUSION

Tan-I, as one of the main components of tanshinone, therefore, may function as an inhibitor of tumour cell proliferation. Recent study revealed that Tan-I exerted anti-tumour activity by suppression of cell proliferation. One study reported that Tan-I inhibited the growth
and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway. Another study demonstrated that Tan-I suppressed the cell proliferation by inducing cyclin D1 proteasomal degradation in an ERK1/2 dependent way in human colorectal cancer cells. Additionally, Tan-I induces apoptosis in Colo 205 cells through both mitochondrial-mediated intrinsic cell death pathways and p21-mediated G0/G1 cell cycle arrest. Despite the repressive activity of Tan-I in cell proliferation in diverse tumour cells have been proverbially reported, the action of Tan-I in ovarian cancer cells proliferation remains hazy.

We discovered that Tan-I inhibited cell proliferation and tumour growth in vitro and in vivo by inducing cell apoptosis and promoting cell autophagy. Our study may provide a neoteric evidence for the anti-proliferative activity of Tan-I in ovarian cancer cells.

Cell apoptosis is an important manifestation of cell death, which is implicated with the development of tumours. Bcl-2 family proteins play an important role in the regulation of the mitochondrial-mediated pathway of apoptosis. Bax and Bcl-2 are the major factors that control the apoptosis. Bax can activate or inhibit Bcl-xl and Bad, while Bcl-2 can inhibit Bax. It is believed that the ratio of Bax/Bcl-2 activity level is a critical determinant of susceptibility to apoptosis, rather than the levels of individual proteins. Caspase family are key regulators in this process. In the present study, our results indicated that Tan-I significantly upregulated the levels of active caspase-3 to inducing cell apoptosis. This result is consistent with that reported in a previous study. Our study found that the expressions of cleaved-caspase-3 and Bax increased, while the expression of Bcl-2 decreased by the Tan-I treatment, and the ratio of Bax to Bcl-2 was significantly enhanced in vitro. The results indicated that Tan-I-induced cell death is under control of caspase-dependent apoptosis and Bax/Bcl-2.

Furthermore, we investigate other mechanisms involved in the inhibition of ovarian cancer cells that treated by Tan-I. Previous studies proved that PI3K signalling is involved in various human diseases including cancers and proliferative diseases. More importantly, PI3K/Akt/mTOR signalling pathway could regulate apoptosis and autophagy in cancer cells. Therefore, inhibition of PI3K signalling is currently considered a very promising approach for treating these diseases and a principal target for drug development. The study reported that Tan II A that is one of the compounds of Dan-shen inhibited tumour growth in gastric carcinoma via downregulating the PI3K/Akt/mTOR in vitro and in vivo. However, it is not clear whether Tan-I affects PI3K/Akt/mTOR signalling pathways. In our study, Tan-I can significantly inhibit PI3K/Akt/mTOR signalling pathways. In additional, the PI3K/AKT/mTOR signalling pathway was considered the main pathway involved in the initiation and regulation of autophagy. The inhibition of AKT inducing autophagy and the activation of AKT inhibiting autophagy have been observed in several studies. The inhibiting of PI3K/AKT/mTOR pathway promotes cell autophagy. In our study, Tan-I dramatically increased the expressions of autophagy-related proteins Beclin1 and ATG7 in a dose-dependent manner and promoted the turnover of LC3-II and p62 degradation in A2780 and ID-8 cells. These data showed that Tan-I can induce autophagy.
Recently, study showed that whether autophagy mediating pro-death or pro-survival is still contentious. However, excessive autophagy could cause autophagic cell death. PI3K/Akt/mTOR signalling pathways is the initiation of autophagy. The inhibiting of PI3K/Akt/mTOR pathways enhanced signal of autophagy activation and induce tumour cell death (Figure 7). This phenomenon has been further confirmed that the subsequent Tan-I treatment plus 3-MA (the inhibitor of class I and III PI3K kinase) significantly inhibited tumour cell proliferation compared with Tan-I alone.

In conclusion, our present results demonstrated that robust evidence supported anti-proliferative effect of Tan-I. The anti-proliferative effect of Tan-I in ovarian cancer may through induce apoptosis by enhancing Caspase-3 cleavage and induce autophagy by inhibiting PI3K/Akt/mTOR pathways, which was proved by a reduction of p-PI3K, p-Akt and p-mTOR by Western blot. Our present results add to the growing body of evidence supporting Tan-I as a potential anti-cancer agent in ovarian cancer.

ACKNOWLEDGEMENTS
This work was supported by Sichuan Science and Technology Program (2019YFS0021, 2018TJPT0013) and Sichuan Crops and Animals Breeding Special Project (2016NYZ0036).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHORS' CONTRIBUTIONS
JZ, YYJ and LZ involved in conceptualization; JZ, YYJ and HC involved in data curation; JZ and YYJ formally analysed; LZ involved in funding acquisition; JZ and YYJ involved in methodology; LZ administrated the project; JZ, YYJ and YCW wrote the original draft; JZ, YYJ and LZ reviewed and edited the writing. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Li Zhang https://orcid.org/0000-0003-2196-2180

REFERENCE
1. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3-14.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018:68:7-30.
3. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413-437.
4. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280-304.
5. Efferth T, Kahl S, Paulus K, et al. Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol Cancer Ther. 2008;7(1):152-161.
6. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1021-1032.
7. Zhang Y, Wei L, Sun D, et al. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes Obes Metab. 2010;12:316-322.
8. Wei Y, Gao J, Qin L, et al. Tanshinone I alleviates insulin resistance in type 2 diabetes mellitus rats through IRS-1 pathway. Biomed Pharmacother. 2017;93:352-358.
9. Cai Y, Zhang W, Chen Z, et al. Recent insights into the biological activities and drug delivery systems of tanshinones. Int J Nanomedicine. 2016;11:121-130.
10. Zhang Y, Jiang P, Ye M, et al. Tanshinones: sources, pharmacokinetics and anti-cancer activities. Int J Mol Sci. 2012;13(12):13621-12666.
11. Jing X, Xu Y, Cheng W, et al. Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers. Cancer Chemother Pharmacol. 2016;77(6):1171-1181.
12. Liang R, Zhao Q, Jian G, et al. Tanshinone IIA Attenuates Contrast-Induced Nephropathy via Nrf2 Activation in Rats. Cell Physiol Biochem. 2018;46:2616-2623.
13. Tang Y, Chen Y, Chu Z, et al. Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol. 2014;723:494-500.
14. Wang F, Ma J, Wang KS, et al. Blockade of TNF-α-induced NF-κB signaling pathway and anti-cancer therapeutic response of dihydrotanshinone I. Int Immunopharmacol. 2015;28:764-772.
15. Lee WY, Chiu LC, Yeung JH. Cytotoxicity of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on HepG2 cells in relation to glutathione perturbation. Food Chem Toxicol. 2008;46(1):328-338.
16. Chen W, Luo Y, Liu L, et al. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev Res (Phila). 2010;3(8):1015-1025.
17. Wang X, Wei Y, Yuan S, et al. Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer. 2005;116(5):799-807.
18. Wang J, Wang X, Jiang S, et al. Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J Neurooncol. 2007;82(1):11-21.
19. Liu JJ, Zhang Y, Lin DJ, et al. Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis. Oncol Rep. 2009;21(4):1075-1081.
20. Yuan SL, Wei YQ, Wang XJ, et al. Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol. 2004;10:2024-2028.
21. Mosaddik MA. In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells. Phytomedicine. 2003;10:682-685.
22. Lee CY, Sher HF, Chen HW, et al. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther. 2008;7(11):3527-3538.
23. Nizamuddinova IT, Lee GW, Son KH, et al. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol. 2008;33(3):485-491.
24. Lu M, Wang C, Wang J. Tanshinone I induces human colorectal cancer cell apoptosis: The potential roles of Aurora A-p53 and survivin-mediated signaling pathways. Int J Oncol. 2016;49:603-610.
25. Li Y, Gong Y, Li L, et al. Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function. Mol Carcinog. 2013;52(7):535-543.
26. Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*. 2016;12(1):1-222.

27. Mizushima N, Levine B. Autophagy in mammalian development and differentiation. *Nat Cell Biol*. 2010;12(9):823-830.

28. Cheng X, Ma X, Ding X, et al. Pacer Mediates the Function of Class III PI3K and HOPS Complexes in Autophagosome Maturation by Engaging Stx17. *Mol Cell*. 2017;65(6):1029-1043.e5.

29. Wilde L, Tanson K, Curry J, et al. Autophagy in cancer: a complex relationship. *Biochem J*. 2018;475:1939-1954.

30. Joffre C, Djavaheri-Mergny M, Pattingre S, et al. The Yin and the Yang of autophagy in cancer cells. *Med Sci (Paris)*. 2017;33:328-334.

31. Liu Y, Levine B. Autosis and autophagic cell death: the dark side of autophagy. *Cell Death Differ*. 2015;22:367-376.

32. Levine B, Yuan J. Autophagy in cell death: an innocent convict. *J Clin Invest*. 2005;115(10):2679-2688.

33. Fulda S, Kögel D. Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. *Oncogene*. 2015;34(40):5105-5113.

34. China Pharmacopoeia committee, 2015. *Pharmacopoeia of People’s Republic of China*. Beijing, China: People Medicinal Publishing House, pp 76, 398-399.

35. Jiang Y, Wang T, Zhang H, et al. A new simple and reliable high-performance liquid chromatography-diode array detection method for the simultaneous quantitative and fingerprint analyses of Salvia przewalskii. *J Chin Pharm Sci*. 2019;28(5):348-359.

36. Wang L, Jiang Y, Zhang Li, Wang T, Yang R, Ding C. High-performance liquid chromatography fingerprints and simultaneous quantification of bioactive compounds in Salvia przewalskii Maxim. *Acta Chromatographica*. 2017;29(3):1-18.

37. Wang W, Li J, Ding Z, et al. Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway. *J Cell Mol Med*. 2019;00:1-12.

38. Kim MK, Park GH, Eo HJ, et al. Tanshinone I Induces cyclin D1 proteasomal degradation in an ERK1/2 dependent way in human colorectal cancer cells. *Fitoterapia*. 2015;101:162-168.

39. Su CC, Chen GW, Lin JG. Growth inhibition and apoptosis induction by tanshinone I in human colon cancer Colo 205 cells. *Int J Mol Med*. 2008;22:613-618.

40. Chen G, Liang Y, Liang X, et al. Tanshinone IIA inhibits proliferation and induces apoptosis through the Downregulation of Survivin in keloid Fibroblasts. *Ann Plast Surg*. 2016;76(2):180-186.

41. Du L, Fei Z, Song S, et al. Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio. *Biomed Pharmacother*. 2017;95:447-452.

42. Vucicevic K, Jakovljevic V, Colovic N, et al. Association of bax expression and Bcl2/Bax ratio with clinical and molecular prognostic markers in chronic lymphocytic leukemia. *J Med Biochem*. 2016;35(2):150-157.

43. Yun N, Kim C, Cha H, et al. Caspase-3-mediated cleavage of PICOT in apoptosis. *Biochem Biophys Res Commun*. 2013;432(3):533-538.

44. Li Q, Zhang J, Liang Y, et al. Tanshinone I exhibits anticancer effects in human endometrial carcinoma HEC-1-A cells via mitochondrial-mediated apoptosis, cell cycle arrest and inhibition of JAK/STAT signalling pathway. *J BUON*. 2018;23(4):1092-1096.

45. Borrie SC, Brems H, Legius E, et al. Cognitive Dysfunctions in Intellectual Disabilities: The Contributions of the Ras-MAPK and PI3K-AKT-mTOR Pathways. *Annu Rev Genomics Hum Genet*. 2017;18:115-142.

46. O’Donnell JS, Massi D, Teng MWL, et al. PI3K-AKT-mTOR inhibition in cancer immunotherapy. *rEdUX*. *Semin Cancer Biol*. 2018;48:91-103.

47. Follo MY, Manzoli L, Poli A, et al. PLC and PI3K/Akt/mTOR signaling in disease and cancer. *Adv Biol Regul*. 2015;57:10-16.

48. Yu JS, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. *Development*. 2016;143:3050-3060.

49. Fulda S. Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signalling. *Mitochondrion*. 2014;19 Pt A:85-87.

50. Bertacchini J, Heidari N, Mediani L, et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia. *Cell Mol Life Sci*. 2015;72:2327-2347.

51. Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. *Pharmacol Ther*. 2014;142:164-175.

52. Su CC, Chiu TL. Tanshinone IIA decreases the protein expression of EGFR, and IGF-1 blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. *Oncol Rep*. 2016;36:1173-1179.

53. Heras-Sandoval D, Pérez-Rojas JM, Hernández-Damián J, et al. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. *Cell Signal*. 2016;24:2694-2701.

54. Janku F, McConkey DJ, Hong DS, et al. Autophagy as a target for anticancer therapy. *Nat Rev Clin Oncol*. 2011;8:528-539.

55. Fan S, Zhang B, Luan P, et al. PI3K/AKT/mTOR/p70S6K Pathway Is Involved in Aji25-35-Induced Autophagy. *Biomed Res Int*. 2015;2015:1-9.

56. Sun H, Wang Z, Yakisch JS. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents. *Anticancer Agents Med Chem*. 2013;13:1048-1056.

57. Roy B, Pattanaik AK, Das J, et al. Role of PI3K/Akt/mTOR and MEK/ERK pathway in Concanavalin A induced autophagy in HeLa cells. *Chem Biol Interact*. 2014;210:96-102.

---

How to cite this article: Zhou J, Jiang Y-Y, Chen H, Wu Y-C, Zhang L. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. *Cell Prolif.* 2020;53:e12739. https://doi.org/10.1111/cpr.12739